SLC7A5 and biliary tract cancer: Furthermore, a recent randomized phase II study reported that the therapeutic response of nanvuranlat as an LAT1 inhibitor was significantly superior to that of the placebo control in patients with previously treated biliary tract cancer and met the primary endpoint of this study [21].